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Introduction: There are increasing concerns world-wide with growing rates of antibiotic
resistance necessitating urgent action. There have been a number of initiatives in the
Republic of Srpska in recent years to address this and improve rational antibiotic
prescribing and dispensing despite limited resources to fund multiple initiatives.
Objective: Analyse antibiotic utilization patterns in the Republic of Srpska following
these multiple initiatives as a basis for developing future programmes in the Republic if
needed.
Methods: Observational retrospective study of total outpatient antibiotic utilization
from 2010 to 2015, based on data obtained from the Public Health Institute, alongside
documentation of ongoing initiatives to influence utilization. The quality of antibiotic
utilization principally assessed according to ESAC, ECDC, and WHO quality indicators
and DU 90% (the drug utilization 90%) profile as well as vs. neighboring countries.
Results: Following multiple initiatives, antibiotic utilization remained relatively stable
in the Republic at 15.6 to 18.4 DIDs, with a decreasing trend in recent years, with
rates comparable or lower than neighboring countries. Amoxicillin and the penicillins
accounted for 29–40 and 50% of total utilization, respectively. Overall, limited utilization
of co-amoxiclav (7–11%), cephalosporins, macrolides, and quinolones, as well as low
use of third and fourth generation cephalosporins vs. first and second cephalosporins.
However, increasing utilization of co-amoxiclav and azithromycin, as well as higher rates
of quinolone utilization compared to some countries, was seen.
Conclusions: Multiple interventions in the Republic of Srpska in recent years have
resulted in one of the lowest utilization of antibiotics when compared with similar
Bojanic´ et al. Antibiotics in Republic of Srpska
countries, acting as an exemplar to others. However, there are some concerns with
current utilization of co-amoxiclav and azithromycin which are being addressed. This
will be the subject of future research activities.
Keywords: antibiotic utilization, antibiotic resistance, cross national comparative study, initiatives, Republic of
Srpska, quality indicators
INTRODUCTION
The discovery of antibiotics is one of the greatest discoveries
of modern medicine. However, since their discovery, it is
acknowledged that bacteria have the ability to become resistant
to antibiotics if they are not used rationally (Rezal et al.,
2015; Godman et al., 2017). Excessive and non-rational use of
antibiotics have resulted in increasing rates of antimicrobial
resistance (AMR) worldwide, with ongoing initiatives to address
this including addressing issues of governance (WHO, 2011,
2015; Collignon et al., 2015; Shallcross et al., 2015; Jinks et al.,
2016). This is essential given the low number of new antibiotics
in development; although there are activities to try and improve
the situation (O’Neill, 2015; Tacconelli et al., 2018). Irrational
use of antibiotics includes the prescribing and dispensing of
antibiotics for upper respiratory tract infections (URTIs), which
are the principal infections seen in ambulatory care and are
predominantly viral in origin (Llor and Bjerrum, 2014; Dyar
et al., 2016; Aabenhus et al., 2017). Inappropriate prescribing,
as well as dispensing without a prescription, are enhanced by
patient pressure, sub-optimal knowledge about antibiotics and
viral infections among key stakeholder groups and fears among
physicians and pharmacists that if they do not prescribe or
dispense an antibiotic patients will go elsewhere (Jorgji et al.,
2014; Yu et al., 2014; Hassali et al., 2015; Bai et al., 2016; Eslami
et al., 2016; Kibuule et al., 2016; Chang et al., 2017).
The costs of AMR in Europe were estimated at e1.5 billion
in 2007, but now rising to e9 billion per year or higher
(Oxford and Kozlov, 2013; Gandra et al., 2014). The lack of
new antibiotics alongside increasing AMR rates has resulted in
increasing morbidity, mortality and costs to healthcare systems
(Aminov, 2010; Gandra et al., 2014; O’Neill, 2015). As a result,
AMR is now seen as one of the biggest public health challenges
(ECDC, 2016), with deaths due to resistant strains envisaged to
reach up to 444 million patients by 2050 if AMR is not addressed
(Taylor et al., 2014; Fitchett and Atun, 2016). This is preventable
with the spread of resistant strains directly correlated with
increasing and irrational use of antibiotics (Costelloe et al., 2010;
Bell et al., 2014; Llor and Bjerrum, 2014). Consequently, raising
awareness and knowledge about AMR and rational antibiotic use
among all key stakeholder groups should result in a reduction in
AMR rates (Huttner et al., 2010; Md Rezal et al., 2015; Rezal et al.,
2015; Godman et al., 2017; WHO, 2018). We are already seeing
multiple activities across Europe including former Soviet Union
Republics to tackle concerns with current antibiotic use and this
will continue (Huttner et al., 2010; Fürst et al., 2015; Abilova et al.,
2018; ECDC, 2018).
The Republic of Srpska is one of the two constituent entities of
Bosnia and Herzegovina, with an estimated population of ∼1.4
million. The Republic has implemented a range of laws and other
activities over the years to regulate health care activities, which
includes enhancing the appropriate use of medicines through
initiatives including introducing good clinical practice guidelines
(MoHSW, 1999, 2008, 2009, 2010; PABH, 2008; Petrusic and
Jakovljevic, 2015). Activities have also been ongoing in other
Balkan countries; however, there are concerns with the practice
of evidence based medicine, the cost consciousness of physicians
even after cost containment policies as well as the principles of
resource allocation among physicians, although this is changing
(Jakovljevic et al., 2016a,b). There are also concerns with the
level of co-payments among patients in the Balkan countries
especially with high cost medicines; although this has not
prevented pharmaceutical markets growing among the Balkan
countries as seen in Bulgaria, Croatia, the Republic of Srpska and
Serbia in recent years, includingmedicines for cardiovascular and
respiratory diseases, cancer and depression (Putrik et al., 2014;
Jakovljevic et al., 2015; Petrusic and Jakovljevic, 2015; Jakovljevic
and Souliotis, 2016; Kostic´ et al., 2017; Pejcic and Jakovljevic,
2017).
Policies and programmes to improve the health of patients
with limited resources in the Republic of Srpska include
improving the availability and affordability of medicines,
improving antibiotic prescribing and dispensing, and raising
awareness on excessive antibiotic utilization and resistance.
A summary of these initiatives are contained in Boxes 1, 2.
The various activities have increased prescribing efficiency as
well as enhanced prescribing in accordance with standard
treatment guidelines, positively impacting on for instance the
rate of polypharmacy in practice (Markovic-Pekovic et al., 2012;
Markovic´-Pekovic´ et al., 2016).
Consequently, the aim of this study was to analyse total
antibiotic utilization in the Republic of Srpska in recent years
and to assess the influence of these various initiatives to
improve antibiotic prescribing and dispensing in the Republic.
Subsequently, compare the findings with those of other European
and neighboring countries to review potential additional
measures that could be introduced in the Republic of Srpska if
needed to further improve the rational use of antibiotics. As a
result, seek to reduce future AMR rates.
METHODS
This was a retrospective observational study on outpatient
antibiotic utilization in the Republic of Srpska from 2010 to 2015,
based on drug utilization data obtained from the Public Health
Institute (PHI). Data collection was based on quantitative and
structural medicinal reports that pharmacies in the Republic send
to the PHI each year for collation (Petrusic and Jakovljevic, 2015).
Consequently, includes total antibiotic utilization in the Republic
and not just prescribed antibiotics.
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BOX 1 | Legal framework for regulation of health care and rational medicine use in the Republic of Srpska.
• Laws, rulebooks, programs, and policies for regulating the health care and rational use of medicines, including antibiotics, adopted by Ministry of Health and Social
Welfare (MoHSW) of the Republic of Srpska (MoHSW, 1999, 2008, 2009, 2010; PABH, 2008).
• Antibiotics can only be dispensed on prescription by pharmacist. There are considerable fines if this is abused (MoHSW 2008; PABH, 2008).
• The Republic of Srpska Inspectorate is the responsible institution for supervising the implementation of this legislation.
• The MoHSW established the National Committee for AMR Control as a national expert body (2015) responsible for monitoring and controlling of AMR and proposing
measures to improve rational antibiotic prescribing and utilization.
• On the proposal of the National Committee, the MoHSW adopted the national Program to reduce AMR resistance in the Republic of Srpska from 2016 to 2020,
harmonized with the WHO Global Strategy for Containment of Antimicrobial Resistance (WHO, 2001) and the Council of Europe Recommendation’s on prudent
use of antimicrobial agents in human medicine (EC, 2002). The aim of this program is to establish and implement high-quality and effective health care for the
population ensuring good control of AMR with an emphasis on rational antibiotic use. The stated objectives are to be reached through improving the intersectoral
control on AMR and antibiotic use in healthcare as well as among veterinary institutions, seeking to reduce morbidity and mortality caused by multiresistant strains
of bacteria, improving education among health workers and associates in the field of AMR, raising awareness on AMR and rational antibiotic use and, also, through
participation of representatives from the Republic of Srpska in international networks and research in the field of AMR.
BOX 2 | Activities to improve rational antibiotic use in the Republic of Srpska.
Activities to enhance rational prescribing
• The set of Clinical Guidelines (CG) with diagnostic and therapeutic principles have been developed for Primary Health Care physicians. These include guidelines for
upper and lower acute respiratory infections in children (acute otitis media, tonsillopharyngitis, community acquired pneumonia), urinary tract infections in children,
as well as urinary tract infections in adults (2004).
• The list of antibiotics funded by the Health Insurance Fund of the Republic of Srpska (HIF) are in accordance with the CG recommendations.
• HIF adopted a positive list of medicines with reference prices comprised of List A and List B. List A is a basic list of medicines for which HIF covers 90 or 100% of
the reference price of the medicine depending on the category of the insured person. List B is a supplementary list, which includes more expensive medicines, for
which HIF covers 50% of the costs for all insured patients. For medicines not included in the positive list, the patient must pay 100% of the price. In addition, if the
price of drug is higher than the reference price adopted by HIF, the patient has to pay the price difference.
• The antibiotics included in List A are: doxycycline, amoxicillin, phenoxymethylpenicillin, benzathine-phenoxymethylpenicillin, cefalexin, sulfamethoxazole with
trimethoprim, and erythromycin. Norfloxacin is included in List B.
Activities to enhance rational dispensing
• There is permanent education of pharmacists and pharmacy technicians on the appropriate management of infectious diseases to address concerns with
knowledge of infectious diseases, especially viral infectious diseases, which has been a concern in other countries (Eslami et al., 2016; Saleem et al., 2016;
Belkina et al., 2017; Hoxha et al., 2018).
• The Pharmaceutical Association of the Republic of Srpska launched the ‘The Guideline for counseling patients in the pharmacy’ as a tool to assist pharmacy
personnel to make decisions whether they can successfully treat patients with non-pharmacological measures and/or with OTC medicines, or whether to refer
them to a family practitioner, in view of concerns with self-medication with antibiotics in the Republic (Markovic´-Pekovic´ and Grubisa, 2012; Damjanovic´ et al.,
2013; Markovic´-Pekovic´ et al., 2017).
Activities of professional associations and key stakeholder groups
• Regular professional meetings, conferences and symposia in order to upgrade the knowledge, habits and attitudes of health professionals (doctors and
pharmacists).
• Publishing articles on AMR and rational antibiotic use in professional journals.
• Discussions concerning current AMR surveillance in the Republic of Srpska among key stakeholder groups and agreement of specific activities to improve AMR
reporting and monitoring.
• The MoHSW and the Public Health Institute (PHI) marking European Antibiotic Awareness Day and World Antibiotic Awareness Week in November each year
starting from 2013 with support of European Centre for Disease Prevention and Control (ECDC).
Activities to enhance public awareness on AMR and rational antibiotic use
• Campaigns are organized to raise awareness about AMR and rational antibiotic use among the general public, patient associations and health professionals.
• Promotional materials (including flyers, infographics, fact sheets, posters, and social media), recommended by ECDC, are provided to patients and health
professionals.
Drug utilization analysis of the PHI data was undertaken using
the ATC (Anatomical Therapeutic Chemical classification)/DDD
(Defined Daily Dose) methodology (WHO, 2017), which is the
internationally accepted methodology for measuring medicine
utilization within and across populations (Godman et al., 2014;
Malo et al., 2014; Versporten et al., 2014; Abilova et al., 2018).
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DDDs are defined as the amount of drug most commonly used in
adults for the most common indication. It is a suitable measure to
describe and compare drug utilization patterns between different
geographical areas and health facilities. Data on outpatient
antibiotic utilization are expressed inDDD/1,000 inhabitants/day
(DIDs) for comparative purposes (Malo et al., 2014; Versporten
et al., 2014; WHO, 2017). DU 90% (drug utilization 90%) was
also used as indicator for assessing the quality of antibiotic
prescribing, ranking antibiotics first by volume of DIDs and then
by how many antibiotics were included in DU 90% (Markovic-
Pekovic et al., 2009; Malo et al., 2014).
Antibiotic utilization and associated quality indicators were
used to compare the Republic of Srpska’s utilization patterns with
that from other European countries, as well as former Soviet
Union Republics, to place this in perspective (Adriaenssens
et al., 2011a,b; Versporten et al., 2014; de Bie et al., 2016;
WHO EUROPE, 2017). The quality of antibiotic prescribing
was assessed using the European Surveillance of Antimicrobial
Consumption (ESAC), European Centre for Disease Prevention
and Control (ECDC), and World Health Organization (WHO)
Europe quality indicators (Adriaenssens et al., 2011a,b; WHO
EUROPE, 2017; ECDC, 2018). These included:
• Total utilization of antibiotics expressed as DIDs,
• Utilization of penicillins (J01C) as a % of total antibiotic use,
• Penicillins combination utilization such as amoxicillin with
clavulanic acid (co-amoxiclav) as a percentage of total
antibiotic use,
• Total utilization of cephalosporins expressed as DIDs,
• Percentage utilization of third- and fourth-generation of
cephalosporins vs. all cephalosporins,
• Total utilization of J01F group (macrolides, lincosamides, and
streptogramins) expressed as DIDs
• Utilization of short-acting macrolides, intermediate and
long-acting macrolides (erythromycin, clarithromycin, and
azithromycin) as a percentage of total antibiotic use,
• Utilization of quinolones (J01M) expressed in DIDs as well
as percentage of fluoroquinolones (J01MA) of total antibiotic
use.
A number of these indicators are due to concerns with the over
use of co-amoxiclav, macrolides, third and fourth generation
cephalosporins as well as fluoroquinolones (Adriaenssens et al.,
2011a; Malo et al., 2014; WHO EUROPE, 2017).
Since multiple initiatives and reforms were instigated over
time in the Republic of Srpska with varying intensity, coupled
with the nature of reported figures, it was impossible to undertake
sophisticated statistical analyses such as time series analyses. As a
result, more simple statistical tests, including trend analyses, were
performed to assess the level of significance, with significance
seen as p < 0.05. This is similar to other health authority
analyses where multiple interventions are conducted over time
with no opportunity for time series analyses (Godman et al., 2010,
2014; Voncina et al., 2011; Bennie et al., 2012; Abilova et al.,
2018).
No specific ethical approval was sought as only aggregated
anonymized data was used for analysis, with Ministry of Health
personnel involved in the study. This is similar to other studies
of this nature (Godman et al., 2010, 2014; Bennie et al., 2012;
Abilova et al., 2018).
RESULTS
The total utilization of antibiotics for systemic use (J01 group)
comprised 98% of total utilization of anti-infectives (J group).
Utilization of the J01 group varied between 15.6 and 18.4 DIDs
during the observed period (Tables 1, 4), lower than a number of
neighboring countries (Figure 1).
Figure 1 compares the utilization in recent years with other
neighboring countries.
The penicillins (J01C) were the most consumed antibiotics
comprising 50% of total antibiotic utilization on average,
followed by other beta-lactam antibiotics (14%). The highest
utilization of penicillins was observed in 2013 with 10.0 DIDs,
while the lowest (7.9 DIDs) observed in 2014. The utilization of
broad-spectrum penicillins (J01CA) was 6.04 DIDs on average
(Table 2). Amoxicillin constituted 95% of this group (5.76
DIDs) (Figure 2), followed by ampicillin (0.28 DIDs). Co-
amoxiclav (J01CR02) ranged from 1.1 to 1.9 DIDs from 2010
to 2015 (Figure 2), while beta-lactamase sensitive penicillins
(J01CE) comprised 5% of total antibiotic use (Table 2), with
phenoxymethylpenicillin the most prescribed antibiotic of this
group.
Utilization of cephalosporins (J01D) decreased from 3.0
DIDs in 2010 to 2.3 DIDs in 2015 (Tables 1, 4). The first-
generation cephalosporins (J01DB) were the most used within
J01D group (67.6%), of which cefalexin was the only one used.
Its utilization decreased from 2.0 DIDs in 2010 to 1.5 DIDs in
2015, which represents a reduction of 25%. Overall, utilization
of the second and third generation of cephalosporins (J01DC
and J01DD) also declined during this period. Regarding the
second-generation cephalosporins, cefuroxime had very stable
utilization ranging from 0.45 to 0.56 DIDs during the study
period, while utilization of cefaclor decreased from 0.15 in
2010 to 0.05 DIDs in 2015 (67%). Overall, third generation
cephalosporins constituted 7.9% of total cephalosporins, or 1.2%
on average of total antibiotics (Table 4). After declining from
2010 to 2014, utilization of third generation cephalosporins
subsequently increased in 2015 (Table 4). The fourth generation
cephalosporins, monobactams, and carbapenems, were not used
at all.
Erythromycin was the most used macrolide (0.68 DIDs)
followed by azithromycin (0.57 DIDs) and clarithromycin (0.32
DIDs). Overall, macrolides constituted 9.4% of total antibiotic
utilization, which is about five times lower than the penicillins.
The use of the macrolides was highest in 2011 (1.78 DIDs) and
then dropped thereafter to 1.55 DIDs in 2014 (Table 1).
Doxycycline was the most used tetracycline (J01A), with
quinolone utilization (J01M) ranging from 1.5 DDDs in 2010 to
1.7 DIDs in 2015 (Table 1), of which 90% were fluoroquinolones.
Ciprofloxacin was themost prescribed fluoroquinolone. The only
sulphonamide (J01E) was a combination of sulfamethoxazole
with trimethoprim, which typically accounted for 7% of total
antibiotic utilization (Table 1). Utilization of aminoglycoside
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FIGURE 1 | Antibiotic utilization in the Republic of Srpska in 2014 and 2015 (in DIDs) vs. neighboring countries in similar years (Taken from Fürst et al., 2015; WHO
EUROPE, 2017; ECDC, 2018).
FIGURE 2 | Amoxicillin vs. co-amoxiclav utilization expressed in DIDs from 2010 to 2015.
antibiotics (J01G) and other antibiotics (J01X) was negligible
(Table 1).
DU90% shows the number of antibiotics included in 90% of
total utilization. Over the observed period, 10 antibiotics were
constantly included in the DU90% profile. DU90% included
10 antibiotics in 2013, 11 in 2014, and 12 during the rest
of the study years. Amoxicillin, amoxicillin with clavulanic
acid (co-amoxiclav), cephalexin, ciprofloxacin, doxycycline,
and sulfamethoxazole with trimethoprim were the most used
antibiotics over the observed period (Table 3).
According to the quality indicators, the total utilization
of beta-lactam antibiotics (penicillins and cephalosporins),
macrolides and fluoroquinolones, expressed as percentage of
total antibiotic use, was very stable over the observed period
(Table 4). However, the use of co-amoxiclav increased from 6.5%
of total antibiotic utilization in 2010 to 11.3% in 2015, which is
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TABLE 1 | Total utilization of antibiotics for systemic use (J01 group) expressed in DIDs and percentages from 2010 to 2015.
ATC group 2010 2011 2012 2013 2014 2015 p-values
DIDs % DIDs % DIDs % DIDs % DIDs % DIDs % DID %
J01C 8.18 46.5 8.34 47.6 7.97 50.6 9.97 54.2 7.86 50.3 8.16 48.7 P = 0.16 P = 0.37
J01D 3.01 17.2 2.45 14.0 2.10 13.4 2.63 14.3 2.06 13.2 2.27 13.5 P = 0.18 P = 0.109
J01M 1.46 8.3 1.64 9.4 1.46 9.3 1.51 8.2 1.61 10.3 1.71 10.2 P = 0.35 P = 0.15
J01F 1.70 9.7 1.78 10.2 1.49 9.5 1.70 9.3 1.55 9.9 1.61 9.6 P = 0.39 P = 0.6
J01A 1.69 9.6 1.55 8.9 1.39 8.9 1.31 7.1 1.27 8.1 1.60 9.5 P = 0.12 P = 0.6
J01E 1.20 6.8 1.41 8.0 1.05 6.7 1.05 5.7 1.03 6.6 1.03 6.2 P = 0.74 P = 0.23
J01X 0.24 1.4 0.25 1.4 0.23 1.5 0.18 1.0 0.21 1.3 0.30 1.8 P = 0.44 P = 0.63
J01G 0.09 0.5 0.10 0.5 0.03 0.2 0.05 0.3 0.04 0.3 0.08 0.5 P = 0.51 P = 0.7
Total J01 17.6 100 17.5 100 15.7 100 18.4 100 15.6 100 16.8 100
J01A, Tetracyclines; J01C, Beta-lactam antibacterials, penicillins; J01D, Other beta-lactam antibacterials (cephalosporins); J01E, Sulfonamides and trimethoprim; J01F, Macrolides,
lincosamides and streptogamins; J01G, Aminoglycoside antibacterials; J01M, Quinolone antibacterials; J01X, Other antibacterials; % = % of antibiotics in that class for the year.
TABLE 2 | Utilization of penicillins (J01CA) expressed in DIDs from 2010 to 2015.
ATC group Pharmacological group DIDs P-values
2010 2011 2012 2013 2014 2015
J01CA Penicillins with extended spectrum 5.62 6.10 5.88 7.56 5.38 5.72 P = 0.99
J01CR Combinations of penicillins, incl. beta-lactamase inhibitors 1.14 1.33 1.23 1.47 1.66 1.89 P = 0.004
J01CE Beta-lactamase sensitive penicillins 1.42 0.91 0.85 0.94 0.82 0.56 P = 0.03
J01CF Beta-lactamase resistant penicillins 001 <0.01 <0.01 <0.01 <0.01 <0.01 P = 0.918
Total J01C 8.2 8.3 8.0 10.0 7.9 8.2
a concern if this trend continues. At the same time, the use of
erythromycin decreased for 37.2% within the macrolide group,
while azithromycin rose proportionally (Tables 3, 4).
Figures 3–5 and Table 5 provide comparisons with similar
and neighboring countries to the Republic of Srpska in recent
years.
DISCUSSION
Total antibiotic utilization was relatively constant during the
study period in the Republic of Srpska (Table 1), with minor
fluctuations, and an overall a decline in total utilization of
5% between 2010 and 2015, with a corresponding reduction
in expenditure on antibiotics (J01) in 2013 vs. 2009 (Petrusic
and Jakovljevic, 2015). In addition, antibiotic utilization in the
Republic was lower than a number of neighboring countries and
former Soviet Union Republics in recent years (Figure 1). This
is in direct contrast with total worldwide antibiotic utilization,
which rose by 36% during the past decade (Laxminarayan et al.,
2016). There appears to be several reasons for this in the
Republic of Srpska. Firstly, health care in the Republic is well-
regulated by a number of policies, strategies, guidelines, and
normatives (Boxes 1,2), despite limited available resources for
such initiatives. The Law on health care and the Law of health
insurance enables all patients to have adequate health care
access in the Republic, including medicines and other types of
treatment (MoHSW, 1999, 2009). Standard treatment guidelines
for the most common clinical problems in ambulatory care
were developed by family physician associations and adopted
by Ministry of Health and Social Welfare (MoHSW) in 2004
in order to improve the quality and rationality of physician
prescribing. Based on these guidelines, only recommended and
essential antibiotics were included in the HIF positive list
of medicines to emphasize rational prescribing and reduce
unnecessary expenditure to help ensure cost-efficient antibiotics
are available for all citizens in the Republic. This approach is
similar to the situation seen in some European countries and
regions with multiple initiatives to enhance the quality and
efficiency of prescribing (Gustafsson et al., 2011; Bjorkhem-
Bergman et al., 2013). However, we are aware that there is variable
implementation of guidelines among a number of European
countries in practice (Francke et al., 2008; Sermet et al., 2010; van
Dijk et al., 2011; Brusamento et al., 2012; Fitzgerald et al., 2014;
Baker et al., 2015). In addition, as mentioned, there are concerns
with issues of evidence based medicine among physicians in
the Balkan countries (Jakovljevic et al., 2016a,b); however, this
appears not to be the case in the Republic of Srpska certainly with
respect to antibiotic prescribing.
Secondly, a number of initiatives and activities have been
implemented in the Republic in order to improve knowledge,
attitudes and practices of pharmacists to reduce antibiotic self-
medication and improve appropriate management of patients
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TABLE 3 | Antibiotic utilization within Drug Utilization (DU90%) profile, expressed in DIDs from 2010 to 2015.
2010 2011 2012 2013 2014 2015
DID % DID % DID % DID % DID % DID %
Amoxicillin 5.14 29.26 5.72 32.67 5.60 35.59 7.38 40.12 5.19 33.20 5.54 33.07
Amoxicillin, clavulanic acid 1.14 6.49 1.33 7.60 1.23 7.82 1.47 7.99 1.66 10.62 1.89 11.28
Cefalexin 2.05 11.67 1.58 9.02 1.31 8.32 1.93 10.49 1.44 9.21 1.53 9.13
Ciprofloxacin 0.96 5.46 1.13 6.45 1.04 6.61 1.11 6.03 1.20 7.68 1.23 7.34
Doxycycline 1.61 9.16 1.48 8.45 1.22 7.75 1.20 6.52 1.11 7.10 1.20 7.16
Sulfamethoxazole, trimethoprim 1.20 6.83 1.41 8.05 1.05 6.67 1.05 5.71 1.03 6.59 1.03 6.15
Azithromycin 0.30 1.71 0.64 3.65 0.50 3.18 0.56 3.04 0.63 4.03 0.76 4.54
Phenoxymethyl-penicillin 1.17 6.66 0.71 4.05 0.66 4.19 0.74 4.02 0.55 3.52 0.53 3.16
Cefuroxime 0.49 2.79 0.56 3.20 0.51 3.24 0.54 2.94 0.48 3.07 0.45 2.69
Erythromycin 1.07 6.09 0.71 4.05 0.61 3.88 0.74 4.02 0.55 3.52 0.43 2.57
Clarithromycin – – 0.35 2.00 0.33 2.10 – – 0.30 1.92 0.35 2.10
Ampicillin 0.48 2.73 0.38 2.17 0.28 1.78 – – – – – –
Norfloxacin 0.30 1.71 – – – – – – – – – –
Ambroxol, doxycycline – – – – – – – – – – 0.38 2.27
DU90 1–12 1–12 1–12 1–10 1–11 1–12
% 90.56 91.36 91.13 90.88 90.46 91.46
Others 13–32 13–31 13–31 11–30 12–30 13–30
% 9.44 8.64 8.87 9.12 9.54 8.54
Total 1–32 1–31 1–31 1–30 1–30 1–30
% 100 100 100 100 100 100
with URTIs (Boxes 1, 2), especially as pharmacists are often
the first health professional patients see with their URTI
(Markovic´-Pekovic´ et al., 2017). This includes the tightening
of self-medication regulations, with self-medication known to
appreciably increase antibiotic utilization in URTIs and similar
conditions (Kalaba et al., 2011; Kibuule et al., 2016; Markovic´-
Pekovic´ et al., 2017). This is different to Albania where self-
medication is common particularly for URTIs, and there are
considerable concerns with pharmacy knowledge regarding
antibiotics and viruses (Jorgji et al., 2014; Hoxha et al., 2015,
2018). There are also concerns with continuing self-medication
in Serbia (Kalaba et al., 2011). Education among pharmacists also
reduced the extent of self-medication with antibiotics in Kenya
especially for URTIs (Mukokinya et al., 2018).
These combined initiatives also appeared to result in high
use of beta-lactam antibiotics and limited use of third and
fourth generation cephalosporins and fluorquinolones in the
Republic in recent years in accordance with agreed quality
indicators (Table 4), comparable or improved prescribing vs.
neighboring countries (Figures 3, 4, and Table 5). We have
also seen reduced expenditure on first and second generation
cephalosporins in Serbia between 2007 and 2012, although
also reduced prescribing of combinations of penicillins (J01CR)
and penicillins with extended spectrums (J01CA) (Jakovljevic
and Souliotis, 2016). The DU90% profile (Table 3) shows
that first and second generation antibiotics were mainly used,
reflecting the antibiotics reimbursed by HIF and contained
in current clinical guidelines (Box 2). This is similar to the
situation with other medicines when prescribing is restricted
and/or where there are high co-payments to rationalize
pharmacotherapy (Sakshaug et al., 2007; Martikainen et al.,
2010; Wettermark et al., 2010; Kalaba et al., 2012; Markovic-
Pekovic et al., 2012; Moon et al., 2014). In Slovenia, prescribing
restrictions for co-amoxiclav, the cephalosporins, macrolides,
and fluoroquinolones, also significantly reduced their use (Fürst
et al., 2015). These findings support other published studies
which suggest that multiple initiatives are typically needed to
positively influence prescribing (Bero et al., 1998; Barton, 2001;
Francke et al., 2008; Godman et al., 2013, 2014; Moon et al.,
2014).
Amoxicillin, which is included in the HIF positive A list,
was the most utilized penicillin in the Republic of Srpska, with
utilization of co-amoxiclav approximately 4 times lower than
amoxicillin. The low utilization of co-amoxiclav in the Republic
compares favorably with neighboring countries (Figure 5).
However, there are concerns with the rise in its utilization
in recent years (Figure 2 and Tables 2, 4). This is due to
concerns with increasing side-effects and resistance leading
to co-amoxiclav now being recommended as a second line
antibiotic after amoxicillin in a number of guidelines (Andrade
and Tulkens, 2011; Desrosiers et al., 2011; NHS Scotland,
2014; GCG prescribing, 2017; ECDC, 2018). There are also
concerns with currently limited prescribing of phenoxymethyl
penicillin in the Republic (Table 3) as it is likely that a high
proportion of infections seen in ambulatory care are likely to be
URTIs (Llor and Bjerrum, 2014; Rezal et al., 2015; Dyar et al.,
2016). These will be areas to address if these trends (Figure 2)
continue.
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TABLE 4 | Quality indicators for antibiotic utilization in the Republic of Srpska from 2010 to 2015.
Quality indicator 2010 2011 2012 2013 2014 2015
Total utilization of antibiotics (J01) (DIDs) 17.6 17.5 15.7 18.4 15.6 16.8
Total utilization of beta-lactam antibiotics (penicillins—J01C and
cephalosporins—J01D) as a % of total antibiotic use
63.7 61.6 64.0 68.5 63.5 62.3
Total utilization of penicillins (J01C) as a % of total antibiotic use 46.5 47.6 50.6 54.2 50.3 48.7
Utilization of combination penicillins (co-amoxiclav—J01CR02) as % of
total antibiotic use
6.5 7.6 7.8 8.0 10.6 11.3
Total utilization of cephalosporins—J01D (DIDs) 3.0 2.5 2.1 2.6 2.1 2.3
Utilization of 3rd and 4th generation cephalosporins (J01DD and
J01DE) as % of total antibiotic use
1.9 1.1 1.3 0.6 0.6 1.4
Utilization of 3rd and 4th generation of cephalosporins as % of total
cephalosporin use
11.0 7.7 9.5 4.1 4.6 10.4
Total utilization of macrolides, lincosamides and streptogramins- J01F
(DIDs)
1.7 1.8 1.5 1.7 1.6 1.6
Total utilization of erythromycin (J01FA01), clarithromycin (J01FA09)
and azithromycin (J01FA10) as % of total antibiotic use
9.3 9.7 9.1 8.9 9.4 9.2
Total utilization of erythromycin as % of total macrolide use, with
corresponding increase in clarithromycin and azithromycin
64.7 40.9 42.0 45.0 36.7 27.5
Total utilization of quinolones J01M—(DIDs) 1.5 1.6 1.5 1.5 1.6 1.7
Total utilization of fluoroquinolones (J01MA) as % of total antibiotic
utilization
7.4 8.4 8.4 7.4 9.3 9.4
FIGURE 3 | Percentage utilization of beta-lactams as a % of total antibiotic utilization across countries (taken from Fürst et al., 2015; WHO EUROPE, 2017; ECDC,
2018).
Encouragingly, given concerns with the development and
spread of resistant strains of C. difficle (Dancer, 2001; Bätzing-
Feigenbaum et al., 2016), there were low rates of cephalosporin
utilization, with rates remaining relatively constant over
the study period (Tables 1, 4). In addition, as mentioned,
the Republic of Srpska had low utilization of third and
fourth generation of cephalosporins in recent years (Table 4),
comparing favorably with neighboring countries (Table 5). There
was also relatively low utilization of macrolides (J01F), with
rates decreasing in recent years but not reaching statistical
significance (Tables 1, 4). This is similar to Serbia with
expenditure on macrolides falling in recent years (Jakovljevic
and Souliotis, 2016). However, the prescribing of azithromycin
is increasing, with a simultaneous decrease in utilization of
erythromycin (Tables 3, 4), resulting in the utilization of
azithromycin exceeding erythromycin in 2014 and 2015. This is
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FIGURE 4 | Utilization of quinolones as a % of total antibiotic utilization across countries (taken from Fürst et al., 2015; WHO EUROPE, 2017; ECDC, 2018).
FIGURE 5 | Percentage combination penicillins (co-amoxiclav J01CR02) as a % of total antibiotic utilization (taken from Fürst et al., 2015; WHO EUROPE, 2017;
ECDC, 2018).
causing concern with increasing resistance rates as well as side-
effects with the macrolides (Albert and Schuller, 2014; ECDC,
2018).
Concerns with the recent increased utilization of co-amoxiclav
and azithromycin, as well as higher use of fluoroquinolones
than some neighboring countries (Table 1), has already resulted
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TABLE 5 | Utilization of third and fourth generation cephalosporins as a % of total
cephalosporins (J01D) (taken from Fürst et al., 2015; WHO EUROPE, 2017;
ECDC, 2018).
Country and year %
Republic of Srpska 2014 4.6
Republic of Srpska 2015 10.4
Serbia 2014 16
Albania 2014 30
Turkey 2014 38
Montenegro 2014 40
Moldova 2014 46
Uzbekistan 2014 63
Azerbaijan 2014 76
Belarus 2014 79
Kyrgyzstan 2014 81
Azerbaijan 2015 82
in planned activities, with their implementation and impact
being monitored. These ongoing and planned activities (Box 2)
should further help with enhancing appropriate antibiotic use
in the Republic of Srpska. Planned activities also include
programmes to improve inter-sectoral control over antibiotic
utilization, including both health and veterinary sectors, as well as
improved undergraduate and postgraduate education regarding
antibiotics and AMR. The development of specific indicators
for monitoring antibiotic utilization is also planned, building
on existing quality indicators for NCDs, as well as monitoring
hospital resistance patterns. These data will be used to revise
and update the clinical guidelines for rational antibiotic use
in the Republic. Planned activities also include improving the
information technology for monitoring of AMR and antibiotic
consumption. The findings will subsequently be shown to health
professionals to emphasize what has been done so far and to
discuss further activities. This is similar to activities in for
instance in Sweden with its monitoring of prescribing in the
regions together with the development of quality indicators to
improve physician prescribing practices (Godman et al., 2009;
Wettermark et al., 2009; Gustafsson et al., 2011; Eriksen et al.,
2017).
Alongside this, pharmacists and family physicians will be
encouraged to communicate more to their patients about
rational antibiotic use and AMR, building on current initiatives.
This will be combined with planned activities to further raise
public awareness regarding the potential harmful effects of
excessive, inappropriate, and unnecessary use of antibiotics.
These programmes will also be the subject of future research
projects.
We believe this study clearly shows that even lower income
countries such as the Republic of Srpska can appreciably
improve rational medicine utilization by introducing multiple
interventions and initiatives, acting as an exemplar to other
European countries and wider.
We are aware of a number of limitations of this study.
These include no access to prescribing data to be able
to assess the quality of antibiotic prescribing against
standard treatment guidelines. However, we believe
our methodology, including the use of total antibiotic
utilization via the PHI datasets, as well as comparisons
with neighboring countries, adds robustness to our findings and
conclusions.
In conclusion, without looking specifically at prescribing
indications, we believe there appears to be rational antibiotic
utilization in the Republic of Srpska in recent years compared to
neighboring countries, with favorable use of penicillins combined
with moderate or low use of co-amoxiclav, cephalosporins
including third and fourth generation cephalosporins,
macrolides, and quinolones. This again demonstrates that
multiple interventions with key stakeholder groups can
favorably improve medicine utilization patterns.
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